Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 222 pages

Showing 201 - 222


gynecologic cancers

Most Commonly Used Ovarian Cancer Cell Lines Do Not Resemble Ovarian Cancer

Researchers from Memorial Sloan-Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became publicly...

breast cancer
gynecologic cancers

Novel Drug Combination Shows Activity in Recurrent Ovarian Cancer

A novel pairing of two investigational cancer drugs in patients with recurrent ovarian cancer showed promising activity and had manageable toxicities, according to a phase I trial published online in the European Journal of Cancer. The combination of the poly(ADP-ribose) polymerase (PARP)...

gynecologic cancers

Trebananib plus Paclitaxel Significantly Delays Disease Progression in Patients with Recurrent Ovarian Cancer

In a phase III trial, treatment with the investigational agent trebananib plus paclitaxel resulted in a statistically significant improvement in progression-free survival in patients with recurrent ovarian cancer, according to Amgen. Trebananib is an investigational peptibody designed to inhibit...

gynecologic cancers
issues in oncology

ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India

Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...

gynecologic cancers

ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer

Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...

gynecologic cancers
head and neck cancer

ASCO 2013: No Increased Risk of Oral HPV Infections Reported in Long-term Partners of Patients with HPV-positive Oropharyngeal Cancers

Spouses and long-term partners of patients diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer were no more likely to test positive for oral HPV infection than people in the general population and have a low risk of HPV-related oropharyngeal cancer, according to the Human Oral...

gynecologic cancers

ASCO 2013: Pazopanib Maintenance Therapy Delays Relapse of Advanced Ovarian Cancer

A phase III clinical trial has found that pazopanib (Votrient), an oral multikinase inhibitor, extends disease-free survival by an average of 5.6 months, compared to placebo, in women with advanced ovarian cancer who had initial successful treatment with surgery and chemotherapy. “Our...

gynecologic cancers

Study: Gold Nanoparticles Can Help Fight Ovarian Cancer

Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current...

breast cancer
gynecologic cancers
pancreatic cancer
prostate cancer

ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...

gynecologic cancers

Study Establishes Basis for Genomic Classification of Endometrial Cancers

A comprehensive genomic analysis of nearly 400 endometrial tumors suggests that certain molecular characteristics, such as the frequency of mutations, could complement current pathology methods and help distinguish between principal types of endometrial tumors, as well as provide insights into...

issues in oncology
breast cancer
gynecologic cancers
pancreatic cancer

Novel Drug Combination Showed Antitumor Activity in Patients with Incurable BRCA-deficient Cancers

When given sequentially, two orally available experimental drugs—sapacitabine and seliciclib—worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers, according to phase I data presented at the AACR Annual Meeting 2013, held in Washington, DC, April...

gynecologic cancers

Novel Two-step Immunotherapy Showed Promise for Patients with Recurrent Ovarian Cancer

A novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, DC,...

gynecologic cancers

New Type of Experimental Drug Active in Platinum-resistant Ovarian Cancers

The antibody-drug conjugate DMUC5754A, a novel member of a relatively new class of drugs, showed activity in women with ovarian cancer, even those with hard-to-treat, platinum-resistant disease, in a phase I trial presented at the AACR Annual Meeting 2013, held in Washington, DC, April 6 to 10....

breast cancer
gynecologic cancers

Mayo Clinic: New DNA Sequences Hone in on Breast, Ovarian Cancer Risk

Researchers at Mayo Clinic Cancer Center have identified new DNA sequences associated with breast cancer and ovarian cancer. The findings, which appear in three studies in the journals PLoS Genetics and Nature Genetics, will help reveal the underlying causes of these diseases and help researchers...

gynecologic cancers
gynecologic cancers
issues in oncology

Moffitt Cancer Center Researchers Analyze HPV Vaccination Disparities among Girls from Low-income Families

Researchers at Moffitt Cancer Center and colleagues at the University of Florida studied health-care providers to determine the factors associated with disparities in human papillomavirus (HPV) vaccination among girls, ages 9 to 17, from low-income families. They found that physician vaccination...

gynecologic cancers

More Than 60% of Ovarian Cancer Patients Do Not Receive Recommended Treatment, Study Shows

Women are 30% less likely to die of ovarian cancer if they have guideline-recommended treatment, yet nearly two-thirds of those with the disease do not receive it, often because they are cared for at hospitals that treat a small number of ovarian cancer patients. These are the findings of a study...

gynecologic cancers
gynecologic cancers

Intraperitoneal Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival

Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark...

gynecologic cancers

Cervical Cancer Patients More Likely to Survive if Treated at High-volume Medical Facilities

Patients with locally advanced cervical cancer have better treatment outcomes and are more likely to survive the disease if they receive care at a high-volume medical center than patients treated at low-volume facilities, according to research presented at the Society of Gynecologic...

gynecologic cancers
lung cancer
issues in oncology

Tackling Tobacco Consumption and Improving Vaccination Access Are Two of the Best Ways to Reduce Global Cancer Burden

Combatting the tobacco industry’s tactics in the world’s poorest countries as well as ensuring the best cancer vaccines are available to those most in need are key in order to reduce the number of cancer deaths worldwide, according to a new report published in the journal Science...

gynecologic cancers
gynecologic cancers

Selumetinib Reported to Benefit Patients with Recurrent Low-grade Ovarian Cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, but the disease is exceptionally difficult to treat when front-line therapy fails. "After surgery, with or without presurgical chemotherapy, when low-grade serous ovarian cancer persists or returns,...

gynecologic cancers
gynecologic cancers

Bevacizumab Significantly Improves Survival for Patients with Recurrent and Metastatic Cervical Cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...

gynecologic cancers

Yale Researchers Identify Genes behind Aggressive Endometrial Cancer

In a major breakthrough for uterine serous carcinoma (USC), a chemoresistant, aggressive form of endometrial cancer, researchers at Yale Cancer Center have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. The collaborative team, which included...

Advertisement

Advertisement



Advertisement